Skip to main content
ALIVUS LIFE SCIENCES LIMITED logo

ALIVUS LIFE SCIENCES LIMITED — Investor Relations & Filings

Ticker · ALIVUS ISIN · INE03Q201024 LEI · 335800RYVA1DKP696G32 BSE.NS Manufacturing
Open in API
Filings indexed 352 across all filing types
Latest filing 2026-05-21 Call Transcript
Country IN India
Listing BSE.NS ALIVUS

About ALIVUS LIFE SCIENCES LIMITED

https://www.alivus.com

Alivus Life Sciences Limited is a pharmaceutical organization dedicated to the formulation, production, and commercialization of a broad spectrum of healthcare solutions. The company operates across multiple therapeutic categories, including gastroenterology, anti-infectives, pain management, and nutritional supplements. Its product range includes diverse delivery formats such as tablets, capsules, syrups, and injectable medications. Alivus Life Sciences focuses on maintaining rigorous quality control protocols and manufacturing excellence to deliver reliable therapeutic outcomes. The company utilizes a robust distribution infrastructure to supply its pharmaceutical products to healthcare providers and patients, prioritizing the accessibility of essential medicines and the continuous expansion of its therapeutic portfolio.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 95% confidence The document is a formal submission under SEBI LODR Regulation 30(6) providing the transcript of the Q4 FY26 earnings conference call, followed by the full call transcript including management commentary and Q&A. This matches the definition of a Call Transcript (CT).
2026-05-21 English
Please find enclosed herewith transcript of Earnings Call held on 15th May, 2026, which is also made available on the website of the Company.
Call Transcript Classification · 83% confidence The document includes the full text of the Q4 FY26 earnings conference call for Alivus Life Sciences, starting with the SEBI Listing Regulations reference “Sub: Transcript of Earnings Call” and followed by the verbatim Q&A transcript. This matches the definition of a conference call transcript. Therefore, it should be classified as a Call Transcript (CT).
2026-05-21 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 85% confidence The document is a letter addressed to stock exchanges under Regulation 30 of SEBI’s Listing Obligations and Disclosure Requirements, informing them of upcoming Investor/Analyst meetings. It is a routine regulatory disclosure rather than an actual financial report, earnings release, management discussion, or presentation. It does not match any other specific category, so under the fallback “general regulatory announcements” it fits Regulatory Filings (RNS).
2026-05-20 English
Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting
Regulatory Filings Classification · 80% confidence The document is a disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) regarding the schedule of investor/analyst meetings. It does not contain any financial statements or report content, nor does it announce a specific financial filing. It is a general regulatory announcement to stock exchanges, fitting the “Regulatory Filings” (RNS) category as a fallback for miscellaneous compliance disclosures.
2026-05-20 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings
2026-05-19 English
Disclosure under Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 - Intimation of Investors/Analyst Meeting
Regulatory Filings
2026-05-19 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.